Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality
source: British Journal of Haematology
year: 2017
authors: Brunson A, Lei A, Rosenberg AS, White RH, Keegan T, Wun T
summary/abstract:Previous reports show increased incidence of venous thromboembolism [VTE, deep-vein thrombosis (DVT) and pulmonary embolus (PE)] in sickle cell disease (SCD) patients but did not account for frequency of hospitalization. We determined the incidence of VTE in a SCD cohort versus matched controls. For SCD patients, risk factors for incident VTE, recurrence and the impact on mortality were also determined. Among 6237 patients with SCD, 696 patients (11·2%) developed incident-VTE: 358 (51·6%) had PE (±DVT); 179 (25·7%) had lower-extremity DVT only and 158 (22·7%) had upper-extremity DVT. By 40 years of age, the cumulative incidence of VTE was 17·1% for severe SCD patients (hospitalized ≥3 times a year) versus 8·0% for the matched asthma controls. Amongst SCD patients, women (Hazard ratio [HR] = 1·22; 95% confidence interval [CI]: 1·05-1·43) and those with severe disease (HR = 2·86; 95% CI: 2·42-3·37) had an increased risk of VTE. Five-year recurrence was 36·8% in patients with severe SCD. VTE was associated with increased risk of death (HR = 2·88, 95% CI: 2·35-3·52). In this population-based study, the incidence of VTE was higher in SCD patients than matched controls and was associated with increased mortality. The high incidence of recurrent VTE in patients with severe SCD suggests that extended anticoagulation may be indicated.
organization: UC Davis School of Medicine, Sacramento, USA; UC Davis Clinical and Translational Sciences Center, Sacramento, USA; VA Northern California Health Care System, Sacramento, USADOI: 10.1111/bjh.14655
read more full text
Related Content
-
Chronic Pain Does not Impact Baseline Circulating Cytokine Levels in Adults With Sickle Cell DiseaseChronic pain affects 50% of adults with ...
-
A Systematic Review of the Classification, Diagnosis, Treatment and Outcome of Osteonecrosis of the Hips in Sickle C...Background: Osteonecrosis (ON) is a prev...
-
CTX001 Continues to Show Promise in Severe SCDA single dose of CTX001, an experimental...
-
Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle ...Global biotherapeutics leader CSL Behrin...
-
SCD Patients Benefit From Early Rivipansel Treatment for VOCs, New Analyses ShowStarting treatment with rivipansel (GMI-...
-
Sickle Cell Disease: Treatments – PAINWeekhttps://www.youtube.com/watch?v=llqCdRNK...
-
Differences in Brain Oxygen Supply May Explain Silent Strokes in SCD PatientsBrain oxygen supply is different in diff...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.